References
- Schoeffski P, Wolter P, Himpe U, et al. Sunitinib-related thyroid dysfunction: A single-center retrospective and prospec-tive evaluation. J Clin Oncol (Meeting Abstracts) 2006; 24:3092.
- Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81–3.
- Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stro-mal tumors.[see comment][summary for patients in Ann Intern Med. 2006 Nov 7; 145 (9): 144; PMID: 17088575]. Ann Intern Med 2006; 145: 660-4.
- de Groot J, Links T, van der Graaf W: Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyrox-ine 10.1093/annonc/md1112. Ann Oncol 2006; 17: 1719–20.
- de Groot JWB, Zonnenberg BA, Plukker JTM, et al. Imatinib induces hypothyroidism in patients receiving levothy-roxine. Clin Pharmacol Therapeut 2005; 78: 433–8.
- Heath H, 3rd, Lee RB, Dimond RC, et al. Conjugated estrogen therapy and tests of thyroid function. Ann Intern Med 1974; 81: 351–4.
- Smith RA, Dumas J, Adnane L, et al. Recent advances in the research and development of RAF kinase inhibitors. Curr Topics Med Chem 2006; 6: 1071–89.
- Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2005; 23: LBA4510.
- Data on file at Bayer.